Evolus: Management Targets Significant Growth in Aesthetics Revenue

Wednesday, 20 March 2024, 18:05
Evolus aims to achieve over $250 million in revenues by 2024, with a positive outlook on the launch of Jeuveau. The post discusses the potential growth trajectory of Evolus towards reaching $700 million in aesthetics franchise revenues by 2028, highlighting why the EOLS stock is seen as a compelling Buy option.
https://store.livarava.com/0bc00928-e6e5-11ee-968c-5254a2021b2b.jpe
Evolus: Management Targets Significant Growth in Aesthetics Revenue

Evolus: Management's Revenue Targets

Evolus management aims for >$250m revenues in 2024, paving the way towards a bold $700m goal in 2028.

Jeuveau Launch

The successful launch of Jeuveau sets a promising tone for Evolus's future performance.

Stock Analysis: EOLS

  • Buy Recommendation: EOLS stock is considered a straightforward Buy.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe